Compugen Ltd. (CGEN) Bundle
Ever wondered how a company can revolutionize drug discovery using computational biology and AI? Compugen Ltd. (CGEN), a clinical-stage drug discovery and development company headquartered in Israel, is doing just that. But how did they get here, who owns them, what's their mission, and, most importantly, how do they make money? Keep reading to discover how Compugen is transforming complex biological data into potential breakthrough therapeutics, leveraging strategic collaborations with pharmaceutical giants like Bayer AG and academic institutions to redefine precision medicine and develop novel cancer treatments.
Compugen Ltd. (CGEN) History
Founding Timeline
Year established
The company was established in 1993.
Original location
The company's original location was in Israel.
Founding team members
The founding team members included Eli Mintz, Anat Cohen-Dayag, and Mor Amitai.
Initial capital/funding
Information regarding the specific initial capital or funding is not readily available in the provided context. However, it's typical for biotech startups to rely on venture capital, government grants, and/or private investments in their early stages.
Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 1993 | Founded | Established as a drug discovery company focusing on computational biology. |
| 2000 | Initial Public Offering (IPO) on NASDAQ | Raised capital to fund research and development programs. |
| 2010 | Entered collaboration with Bayer | Focused on discovering and developing novel cancer immunotherapies. |
| 2013 | Began clinical development of COM701 | Transitioned from discovery to clinical-stage development. |
| 2018 | Entered collaboration with Bristol-Myers Squibb | Further validation of its pipeline and technology platform in immunotherapy. |
| 2020 | Presented positive Phase 1 data for COM701 | Demonstrated early clinical efficacy and safety of its lead candidate. |
| 2021 | Continued expansion of clinical programs | Advanced clinical trials for COM701 in combination therapies. |
| 2024 | Announced clinical trial updates | Showcased ongoing progress and potential of its therapeutic candidates, including COM701. |
Transformative Moments
Several transformative moments have shaped the company's trajectory:
- Strategic Shift to Immunotherapy: A pivotal decision was the company's strategic focus on cancer immunotherapy, leveraging its computational biology platform to identify novel drug targets.
- Key Partnerships: Collaborations with major pharmaceutical companies like Bayer and Bristol-Myers Squibb provided significant validation, funding, and resources for clinical development.
- Clinical Advancement of COM701: The progression of COM701, a novel immunotherapy candidate, into clinical trials marked a crucial step in the company's evolution from a discovery-focused company to a clinical-stage biopharmaceutical company.
- Financial Milestones: Achieving key financial milestones such as the IPO and securing substantial funding through partnerships has enabled sustained investment in research and development.
For insights into the company's financial standing, consider reading: Breaking Down Compugen Ltd. (CGEN) Financial Health: Key Insights for Investors
Compugen Ltd. (CGEN) Ownership Structure
Understanding the ownership structure of a company like Compugen Ltd. provides valuable insights into its control and governance. Here’s a breakdown of key aspects related to Compugen's ownership and leadership. For a deeper dive into who is investing in Compugen and their motivations, check out: Exploring Compugen Ltd. (CGEN) Investor Profile: Who’s Buying and Why?
Compugen's Current Status
Compugen Ltd. is a public company, trading on the Nasdaq under the ticker symbol CGEN.
Compugen's Ownership Breakdown
Understanding the distribution of ownership in Compugen Ltd. can offer insights into the stability and potential influences on the company's strategic decisions.
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Owners | 74.88% | Includes investment firms, mutual funds, and other institutions. Top institutional holders include:
|
| Individual Insiders | 0.66% | Shares held by company executives and board members. |
| Public/Retail Investors | Remaining percentage | Individual investors who hold shares. |
Compugen's Leadership
The leadership team at Compugen is responsible for the strategic direction and operational execution of the company.
- Anat Cohen-Dayan, Ph.D. serves as President and CEO.
- Ari Krashinsky, MBA, CPA is the Executive Vice President and CFO.
Compugen Ltd. (CGEN) Mission and Values
Compugen Ltd. focuses on discovering and developing innovative therapeutics by leveraging predictive computational discovery platforms to improve patient outcomes. The company values innovation, collaboration, and a commitment to making a difference in healthcare.
Compugen's Core Purpose
Official mission statement
While a specific, formally published mission statement for Compugen Ltd. isn't readily available in recent official documents, we can infer their core mission from their activities and stated goals. Compugen's mission is centered around:
- Pioneering the discovery of novel drug targets through computational methods.
- Developing innovative immunotherapies to treat cancer.
- Improving patient outcomes by translating scientific discoveries into clinical solutions.
Vision statement
Compugen's vision can be understood as striving to:
- Become a leader in predictive drug discovery, particularly in the field of immuno-oncology.
- Create a pipeline of first-in-class therapeutics that address unmet medical needs.
- Transform cancer treatment by harnessing the power of the immune system.
Company slogan/tagline
Based on available information, Compugen doesn't appear to have a widely publicized official slogan or tagline. However, considering their focus, a fitting tagline might be:
- 'Predicting the Future of Immunotherapy'
- 'Innovation for a Healthier Tomorrow'
- 'Unlocking the Power of the Immune System'
To delve deeper into Compugen Ltd. and its investors, check out: Exploring Compugen Ltd. (CGEN) Investor Profile: Who’s Buying and Why?
Compugen Ltd. (CGEN) How It Works
Compugen Ltd. (CGEN) operates as a clinical-stage drug discovery and development company, utilizing its computational platform to discover and develop therapeutics, particularly in the field of immuno-oncology.
Compugen's Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| COM701 | Patients with solid tumors | A first-in-class anti-PVRIG antibody designed to block the interaction of PVRIG with its ligands, PVRL1 (nectin-1) and PVRL2 (nectin-2), to unleash T and NK cell responses against tumors. It is being evaluated in combination with other therapies. |
| COM902 | Patients with various cancers | A monoclonal antibody targeting TIGIT, designed to enhance immune responses against cancer cells. It is currently in early-stage clinical trials to assess its safety and efficacy, both as a monotherapy and in combination with other anti-cancer agents. |
| Bayer Collaboration | Oncology | Collaboration with Bayer focuses on the discovery and development of novel antibody-based cancer immunotherapies against undisclosed Compugen-discovered drug targets. |
Compugen's Operational Framework
Compugen's operational framework is built around its computational discovery platform, which is used to identify novel drug targets. The company focuses on:
- Target Discovery: Utilizing computational biology and bioinformatics to identify novel immune checkpoints and other drug targets.
- Antibody Development: Developing therapeutic antibodies, such as COM701 and COM902, to modulate the activity of these targets.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its drug candidates.
- Strategic Collaborations: Partnering with other pharmaceutical companies, like Bayer, to expand its research and development efforts.
The company's revenue primarily comes from collaborative agreements and potential milestone payments, as it continues to advance its pipeline of therapeutic candidates through clinical development.
Compugen's Strategic Advantages
Compugen's strategic advantages include:
- Computational Platform: A proprietary platform that enables the discovery of novel drug targets with a focus on immuno-oncology.
- First-in-Class Assets: Development of first-in-class therapeutic candidates like COM701, targeting the PVRIG pathway.
- Strategic Partnerships: Collaborations with major pharmaceutical companies enhance research and development capabilities and provide financial support.
- Experienced Management Team: A team with expertise in computational biology, drug development, and clinical research.
These advantages enable Compugen to innovate in the competitive biopharmaceutical industry and potentially deliver novel cancer immunotherapies. For insights into the company's financial standing, consider reading Breaking Down Compugen Ltd. (CGEN) Financial Health: Key Insights for Investors.
Compugen Ltd. (CGEN) How It Makes Money
The company primarily generates revenue through licensing, research and development collaborations, and milestone payments associated with its therapeutic programs.
Revenue Breakdown
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Licensing Fees | Varies | Dependent on New Agreements |
| Research and Development Collaborations | Varies | Dependent on Active Programs |
| Milestone Payments | Varies | Dependent on Clinical Trial Progress |
Business Economics
The business economics of the company are driven by its ability to:
- Discover novel drug targets using its computational platform.
- Secure partnerships with pharmaceutical companies for further development and commercialization.
- Achieve clinical milestones that trigger payments.
The company's success is closely tied to the validation and clinical progress of its drug candidates, as well as its ability to forge strategic alliances. Understanding the Mission Statement, Vision, & Core Values of Compugen Ltd. (CGEN). is also crucial to grasping their business approach.
Financial Performance
Key aspects of the company's financial performance include:
- Revenue recognition is irregular, contingent upon achieving specific milestones in its collaborative agreements.
- R&D expenses constitute a significant portion of its operating costs, reflecting its focus on drug discovery and development.
- The company's financial stability is partly reliant on its cash reserves and its ability to secure additional funding through partnerships or equity offerings.
Compugen Ltd. (CGEN) Market Position & Future Outlook
As of April 2025, Compugen Ltd. faces a dynamic market landscape, balancing promising opportunities with inherent challenges that will shape its future trajectory. Its innovative approach to computational drug discovery positions it uniquely, though competition and market volatility remain key factors.
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Compugen | Approx. 1-2% (Niche Player) | Pioneering computational discovery platforms for novel drug targets, particularly in immuno-oncology. |
| Bristol Myers Squibb | Approx. 15-20% | Extensive portfolio of approved oncology drugs and a robust pipeline, coupled with significant financial resources for R&D and commercialization. |
| Merck & Co. | Approx. 13-18% | Key player in immuno-oncology with blockbuster drugs like Keytruda, demonstrating strong market presence and clinical trial expertise. |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Advancements in AI and machine learning to accelerate drug discovery and target identification. | High attrition rates in drug development, with many promising candidates failing in clinical trials. |
| Growing demand for personalized medicine and targeted therapies, aligning with Compugen's focus on novel target discovery. | Intense competition from larger pharmaceutical companies with greater resources and established market positions. |
| Strategic partnerships and collaborations to expand pipeline and access new markets. | Regulatory hurdles and evolving requirements for drug approval, increasing the time and cost of development. |
Industry Position
Compugen operates within the highly competitive biotechnology sector, focusing on early-stage drug discovery. Key aspects of its industry standing include:
- Niche Player: Compugen occupies a niche position, specializing in computational target discovery rather than broad-spectrum drug development.
- Innovation Focus: The company's strength lies in its ability to identify novel drug targets using computational methods, giving it a competitive edge in early-stage research.
- Partnerships: Collaborations with larger pharmaceutical companies are crucial for advancing its discoveries through clinical trials and commercialization.
To gain deeper insights into the investors and motivations behind Compugen, explore: Exploring Compugen Ltd. (CGEN) Investor Profile: Who’s Buying and Why?
Compugen Ltd. (CGEN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.